ESTRO 2024 - Abstract Book

S1119

Clinical - Gynaecology

ESTRO 2024

A low pretreatment musculoskeletal area is associated with poor survival outcomes between women with locally advanced cervical cancer, treated with chemoradiation and brachytherapy. The identification of modifiable factors, as sarcopenia, is important for us, because can lead to a development of improvement strategies for oncologic outcomes in our population.

Keywords: Cervical Cancer, Sarcopenia

References:

Anjanappa M, Corden M, Green A, Roberts D, Hoskin P, McWilliam A, Choudhury A. Sarcopenia in cancer: Risking more than muscle loss. Tech Innov Patient Support Radiat Oncol. 2020 Nov 9;16:50-57.

Ackermans LLGC, Rabou J, Basrai M, Schweinlin A, Bischoff SC, Cussenot O, Cancel-Tassin G, Renken RJ, Gómez E, Sánchez-González P, Rainoldi A, Boccia G, Reisinger KW, Ten Bosch JA, Blokhuis TJ. Screening, diagnosis and monitoring of sarcopenia: When to use which tool? Clin Nutr ESPEN. 2022 Apr;48:36-44. Han Q, Kim SI, Yoon SH, Kim TM, Kang HC, Kim HJ, Cho JY, Kim JW. Impact of Computed Tomography-Based, Artificial Intelligence-Driven Volumetric Sarcopenia on Survival Outcomes in Early Cervical Cancer. Front Oncol. 2021 Sep 24;11:741071. Matsuoka H, Nakamura K, Matsubara Y, Ida N, Nishida T, Ogawa C, Katsi K, Kanazawa S, Masuyama H. Sarcopenia Is Not a Prognostic Factor of Outcome in Patients With Cervical Cancer Undergoing Concurrent Chemoradiotherapy or Radiotherapy. Anticancer Res. 2019 Feb;39(2):933-939. Lee J, Chang CL, Lin JB, Wu MH, Sun FJ, Jan YT, Hsu SM, Chen YJ. Skeletal Muscle Loss Is an Imaging Biomarker of Outcome after Definitive Chemoradiotherapy for Locally Advanced Cervical Cancer. Clin Cancer Res. 2018 Oct 15;24(20):5028-5036.

3172

Digital Poster

Safety and efficacy of modern concurrent radiochemotherapy with Cisplatin and Gemcitabine

Elena Riggenbach 1 , Lucas Mose 1 , Sara Imboden 2 , Franziska Siegenthaler 2 , Elke Krause 2 , Saskia Schlootz 3 , Manuela Rabaglio 3 , Nikola Cihoric 1 , Kristina Lössl 1 , Julian Wampfler 3 1 Inselspital, Bern University Hospital and University of Bern, Department of Radiation Oncology, Bern, Switzerland. 2 Inselspital, Bern University Hospital and University of Bern, Department of Obstetrics and Gynecology, Bern, Switzerland. 3 Inselspital, Bern University Hospital and University of Bern, Department of Medical Oncology, Bern, Switzerland

Purpose/Objective:

The standard treatment for locally advanced cervical cancer (CC) is concurrent platinum-based chemoradiation and brachytherapy. Systemic treatment intensification of combined cisplatin and gemcitabine (CG) increases the radiosensitizing effect and addresses the predominant distant failure pattern. This approach has shown improved